A number too good to check
Scroll through health X for more than a few minutes this month and you will hit some version of the same claim, usually in red-alert emoji: high cholesterol doesn't kill old people, low cholesterol does, and statins are one of the most overprescribed drugs in history. One post making the rounds, from an account with more than 200,000 followers, cleared 3,500 likes and 1,400 bookmarks in a few days.1 The bookmark count is the tell. People aren't just liking this. They're saving it to win an argument with their doctor.
Almost every version of the claim traces back to a single source: a 2016 systematic review that pooled 68,094 older adults and reported that the people with the highest LDL cholesterol tended to live the longest.2 The headline that gets quoted is that in 92% of the participants, high LDL was linked to lower or equal mortality, never higher. It is a clean, screenshot-ready number, and it is, as far as it goes, accurate.
The problem is everything that gets stapled onto it. The leap from "older people with high LDL lived longer in these cohorts" to "high LDL is therefore good for you and statins are a scam" is not a small step. It is the entire argument, and it is the part the data does not support. This issue is about the gap between the number and the conclusion, because that gap is where the hype lives.
Three real numbers, three different stories. The art of the viral claim is keeping the first one and hiding the other two.2,5,12
Who actually wrote the keystone
The 2016 review was published in BMJ Open by Uffe Ravnskov and sixteen co-authors.2 It searched the literature for cohort studies of LDL and mortality in people over 60, ended up with 19 studies covering 30 cohorts, and tallied the direction of the association. In 16 of those 30 cohorts, representing 92% of the participants, higher LDL went with lower all-cause death. The rest showed no clear link. None showed high LDL predicting more death.
Before we get to whether the analysis holds up, it is worth knowing who ran it. The lead author, Uffe Ravnskov, founded an organization called THINCS, The International Network of Cholesterol Skeptics, in 2003. Its founding purpose is to dispute the idea that cholesterol causes heart disease.2,4 Nine of the co-authors on this "systematic review" are THINCS members, including two of the most prominent public statin critics in the world. This is the equivalent of a tobacco-funded panel publishing a review on whether smoking is really that bad. It does not automatically make them wrong. It does mean the review needs to be read with both eyes open.
Design. A vote-counting review of 19 observational cohort studies (30 cohorts) of adults aged 60 and up. No pooled effect estimate; the authors counted which direction each association pointed.2
Result: In 16 of 30 cohorts (92% of participants), the highest-LDL group had the lowest all-cause mortality. The authors concluded the cardiovascular benefits of statins "have been exaggerated."
Limitation: The search string literally excluded the word "trial," removing the entire randomized literature by design. Cardiovascular death, the outcome that actually matters here, was reported in only a minority of the included studies, and some of those showed harm from high LDL.
That search string deserves its own moment. The query the authors used to find studies ended with the operators NOT animal NOT trial.3 Read that again. A review arguing that statin trials have overstated their benefits built its evidence base by explicitly filtering out the word "trial." Oxford's Centre for Evidence-Based Medicine, in a formal post-publication review, flagged this as a high risk of bias for missing relevant evidence.3
It gets more specific. The authors excluded a 2015 study by Postmus and colleagues that used genetics to test the same question and found high LDL raised mortality even in old age, despite that study meeting their stated criteria.3,6 Meanwhile they included a single Danish cohort that made up more than 60% of all their participants, even though that cohort lacked the statistical adjustments their own protocol required, and even though that same cohort reported statins improved survival in nearly every group.3 Independent fact-checkers have rated the viral derivative claim "Misleading."4
A review claiming statin trials are oversold found its evidence by searching for everything except trials.
On the keystone study's methodologyWhy sick people have low cholesterol
Set the authors aside for a moment, because even an honest version of this study would hit the same wall. It is the single most important idea in this entire issue, and it is not complicated: in older people, low cholesterol is very often a result of being ill, not a cause of dying.
Cancer that hasn't been diagnosed yet, chronic inflammation, malnutrition, a failing liver, and frailty all lower serum cholesterol, sometimes for months or years before death.15 Low total cholesterol is recognized as an independent marker of frailty in hospitalized older adults and tracks with malnutrition and disability.15 An Italian aging study described low cholesterol in the elderly as a clinical warning sign. A 2020 review in the Journal of the American Geriatrics Society titled this exact phenomenon "a paradox of healthy aging" and laid the inverse association at the feet of reverse causation.15
So when you measure a 78-year-old's LDL once and follow the group, the low-LDL bucket is quietly stuffed with people who are already dying of something else, and that drags the low-LDL group's mortality up. The high-LDL group looks healthier by comparison not because LDL protects them, but because they are the ones who weren't yet wasting away. The viral version reads this backwards. It treats a marker of who is already sick as if it were a recipe for staying well.
The experiment biology already ran
Here is how you break the reverse-causation trap. You need to know someone's LDL exposure across their whole life, set before any illness could have moved it. Biology hands you exactly that, through the genes that nudge LDL up or down from birth. The method is called Mendelian randomization, and because gene variants are dealt out essentially at random at conception, it works like a natural lifelong randomized trial.
Design. A meta-analysis of genetic data on 312,321 participants, estimating the effect of lifelong lower LDL on coronary heart disease.5
Result: Each 1 mmol/L (about 39 mg/dL) of genetically lower LDL was tied to roughly 54% lower coronary disease risk, about three times the per-unit benefit seen in short statin trials, precisely because the exposure lasts a lifetime.
Limitation: Coronary disease, not all-cause mortality, was the endpoint; the design assumes the gene variants act mainly through LDL.
Design. The study the keystone review left out. It used a 51-variant LDL genetic score to test whether high LDL still matters in old age.6
Result: LDL-raising variants got rarer with age, because carriers die off sooner. People genetically built for longevity carried lower LDL scores, and the highest LDL genetic score carried about 13% higher mortality even past 90. The authors concluded LDL contributes to mortality "throughout life, including in the oldest old."
Limitation: A genetic score reflects lifelong exposure rather than a single late-life reading. That is the entire point, but it means it can't speak to what one measurement means in a frail 85-year-old.
A third Mendelian study, published in 2021, found that genetically higher LDL predicted shorter parental lifespan, and the effect shrank once you accounted for coronary disease, exactly what you'd expect if LDL shortens life by clogging arteries.7 When you strip out reverse causation, the protective signal doesn't just weaken. It flips.
What randomization actually showed
Genetics aside, we also have the thing the keystone review filtered out: randomized trials, where you give some elderly patients a statin and some a placebo and wait.
Design. Individual-patient data from 28 randomized trials, nearly 187,000 people, broken out into six age bands including over-75.9
Result: Each 1 mmol/L drop in LDL cut major vascular events by about 21% overall, with a significant benefit in every age band, including the over-75s. The per-year benefit tapered somewhat with age but never vanished.
Limitation: In the over-75 group with no prior vascular disease, the primary-prevention data were thin and not statistically robust. This is the one honest soft spot, and we'll come back to it.
Design. 5,804 adults aged 70 to 82 randomized to pravastatin or placebo for about 3.2 years.8
Result: The statin cut the primary cardiovascular composite by 15%. Benefit was strongest in those with existing vascular disease.
Limitation: Over barely three years there was no all-cause mortality benefit and no stroke reduction, plus a transient excess of cancer diagnoses that later analyses judged a chance finding. Funded by Bristol-Myers Squibb.
The genuinely clean test of statins for prevention in healthy older people is a trial called STAREE, which randomized nearly 10,000 Australians over 70 with no prior heart disease.10 It has not fully reported as of this writing. Anyone telling you the elderly-prevention question is definitively settled, in either direction, is getting ahead of the data. What we can say is that across every age band actually tested, lowering LDL lowered cardiovascular events.
The most honest part of the hype
One strand of the viral claim is better than the rest, and it deserves a fair hearing. In 2015, a group analyzed the survival curves from 11 statin trials and calculated that, on average, taking a statin postponed death by a median of about 3.2 days in primary prevention and 4.1 days in secondary prevention over the trials' run.12 "Statins buy you four days" comes from real arithmetic.
But two things gut the soundbite. First, those trials ran about four to six years. People take statins for decades, and atherosclerosis is cumulative, so measuring the payoff over a few years dramatically undercounts it. The genetic data, which captures lifelong exposure, implies the real gain is far larger. Second, an average across everyone hides a lopsided distribution. Most people in a trial were never going to have a heart attack in those years, so they contribute zero days. The minority who avoid a fatal event don't gain four days. They gain years. Averaging the two groups produces a number that is technically true and deeply misleading.
Even the author of that analysis drew a reasonable conclusion: for patients with limited life expectancy or bad side effects, it's worth reconsidering the statin. That is sensible deprescribing advice for frail, elderly, or dying patients. It is not "statins are useless for everyone."
Conflicted authorship
The keystone review was led by the founder of a cholesterol-skeptic organization, with nine member co-authors. The conclusion preceded the search.
The "NOT trial" filter
The literature search excluded the word "trial," structurally removing the randomized evidence that contradicts the thesis.
Reverse causation
Low late-life cholesterol is often a symptom of undiagnosed cancer, frailty, or malnutrition, not a cause of death. The arrow points the other way.
All-cause vs. cardiovascular
The 92% figure is about all-cause death. Cardiovascular death, where LDL does its damage, was barely analyzed, and where measured, high LDL sometimes looked worse.
The sliver worth keeping
It would be its own kind of hype to tell you the skeptics have nothing. They have one real point, and it is narrow. Whether starting a statin in a healthy person over 75 with no heart disease meaningfully extends their life is genuinely uncertain. The US Preventive Services Task Force gives that exact group an "I" rating, meaning insufficient evidence.13 A 2024 post-hoc analysis of the healthy-elderly ASPREE cohort found a U-shaped curve, where very high LDL still tracked with more cardiovascular death, but moderate LDL looked fine, supporting a go-easy approach in robust elders rather than chasing rock-bottom numbers.11
So the defensible version is something like: in a frail 80-year-old with a short life expectancy, the case for starting a statin purely for prevention is weak, and deprescribing is reasonable. Notice that this is also, almost word for word, what the guidelines already say.13,14 A 2024 expert consensus from lipid and geriatrics specialists recommends individualized decisions, frailty assessment, and deprescribing for those with life-limiting illness, while affirming that high LDL still predicts events in the over-75s.14 The kernel of truth isn't a suppressed secret. It's the standard of care.
"Uncertain in the frailest 80-year-olds" is a real finding. "High LDL is your fountain of youth" is a meme wearing its lab coat.
Dr. Maren ColeDr. Cole's assessment
The viral claim is a magic trick built on one honest number. Yes, in older populations, low LDL often travels with higher death rates, and that pattern shows up even in healthy-elderly data. If the claim stopped there, I'd call it a real and interesting epidemiological finding. It doesn't stop there.
It laminates that observation onto two false conclusions: that high LDL is therefore protective, and that statins are useless. Both collapse the moment you use a method that defeats reverse causation. Mendelian randomization, the closest thing to a lifelong randomized trial, shows high LDL shortens life through atherosclerosis. Actual randomized trials show lowering LDL cuts cardiovascular events in every age band tested. And the keystone study driving the whole narrative was written by self-identified cholesterol skeptics, excluded the trial literature by search design, and dropped the one genetic study that contradicted it.
The narrow, legitimate point, that prevention in the frail oldest-old is genuinely unsettled, is real, but it is also already the guideline position. The leap from there to the meme is where this earns a Marketing Hype rating. Don't change your cardiovascular care based on a bookmark.
Low cholesterol in old age is often a sign someone is already sick, not the reason they're dying. The genetics and the trials both say lifelong high LDL shortens life. The 92% is real; the fountain of youth it supposedly proves is not.
- 1. Public posts and engagement metrics on X (Twitter), June 2026, circulating the "high LDL in the elderly = longer life / statins overprescribed" claim. Engagement figures from X recent-search.
- 2. Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between LDL-cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016;6(6):e010401.
- 3. Centre for Evidence-Based Medicine (Oxford). Post-publication peer review of Ravnskov et al. 2016 — search-bias, exclusion of Postmus 2015, and confounding critiques.
- 4. Science Feedback. Fact-check rating the derivative viral claim "Misleading"; Science Media Centre expert reactions (Baigent, Chico, Danesh).
- 5. Ference BA, et al. Effect of long-term exposure to lower LDL-C beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639.
- 6. Postmus I, et al. LDL cholesterol still a problem in old age? A Mendelian randomization study. Int J Epidemiol. 2015;44(2):604-612.
- 7. Daghlas I, et al. Low-density lipoprotein cholesterol and lifespan: a Mendelian randomization study. Br J Clin Pharmacol. 2021;87(10):3916-3924.
- 8. Shepherd J, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
- 9. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 RCTs. Lancet. 2019;393(10170):407-415.
- 10. STAREE (Statins for Reducing Events in the Elderly) trial — protocol and status; primary results pending as of mid-2026.
- 11. ASPREE Investigator Group. LDL cholesterol and mortality outcomes among healthy older adults: a post hoc analysis of the ASPREE trial. J Gerontol A Biol Sci Med Sci. 2024;79(4):glad268.
- 12. Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials: an analysis of end point postponement. BMJ Open. 2015;5(9):e007118.
- 13. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults. JAMA. 2022;328(8):746-753.
- 14. National Lipid Association / American Geriatrics Society expert consensus on statin use in adults over 75. J Clin Lipidol. 2024.
- 15. Orkaby AR. The highs and lows of cholesterol: a paradox of healthy aging? J Am Geriatr Soc. 2020;68(2):236-237; plus literature on low cholesterol as a frailty/malnutrition marker in the elderly.